These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18621639)

  • 1. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
    Cartwright TH; Genther R
    Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
    Saif MW; Peccerillo J; Potter V
    Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.
    Langerak A; River G; Mitchell E; Cheema P; Shing M
    Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab.
    Brugger W
    Tumori; 2010; 96(3):473-7. PubMed ID: 20845811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.
    Nielsen DL; Pfeiffer P; Jensen BV
    Ann Oncol; 2009 Apr; 20(4):798. PubMed ID: 19254943
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab (Vectibix) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of panitumumab in the management of metastatic colorectal cancer.
    Saif MW; Cohenuram M
    Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab.
    Helbling D; Borner M
    Ann Oncol; 2007 May; 18(5):963-4. PubMed ID: 17488734
    [No Abstract]   [Full Text] [Related]  

  • 16. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.
    Ishiguro M; Watanabe T; Yamaguchi K; Satoh T; Ito H; Seriu T; Sakata Y; Sugihara K
    Jpn J Clin Oncol; 2012 Apr; 42(4):287-94. PubMed ID: 22327124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
    George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
    J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
    Cohenuram M; Saif MW
    Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.
    Schwartzberg LS; Stepanski EJ; Fortner BV; Houts AC
    Support Care Cancer; 2008 Apr; 16(4):393-8. PubMed ID: 17909865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.